Bulk Anti-Human CD25 (7G7B6) Antibody

Human

CD25

>1mg/ml

Mouse IgG2a

Mouse

Daclizumab Biosimilar - Research Grade (ICH5021), Camidanlumab Biosimilar - Research Grade (ICH5090), Basiliximab Biosimilar - Research Grade (ICH5189), Inolimomab Biosimilar - Research Grade (ICH5605), Vopikitug Biosimilar - Research Grade (ICH5990)

Aggregation level ≤ 5%

Recombinant human peripheral blood mononuclear cells (PBMCs)

IL-2Rα is expressed on activated mature T and B lymphocytes, during early stages of thymocytes development, pre-B cells, and in activated CD4+ memory T-lymphocytes

ICH3001-100ml ICH3002-100ml ICH3003-100ml

P01589

3559

Blue ice

This bulk anti-human CD25 antibody is the mouse monoclonal clone 7G7B6, a mouse IgG2a that recognizes the human interleukin-2 receptor alpha chain (IL-2Rα/CD25, UniProt P01589). 7G7B6 is a long-established, widely characterized clone binding an epitope on human CD25 that is distinct from the IL-2 binding site, making it useful for detecting receptor expression without necessarily competing with ligand. It is validated across a broad application set (ELISA, flow cytometry, immunofluorescence, immunoprecipitation, and Western blot), supporting both surface phenotyping and biochemical characterization of the receptor. Supplied at research-grade low endotoxin and in bulk milligram-to-gram quantities, it is suited to functional and cell-based studies that require large, consistent lots, including activation-marker and regulatory T cell (Treg) profiling, receptor-tracking assays, and antibody-based enrichment or capture workflows. As a human-reactive reagent it is intended for in-vitro and ex-vivo human cell work rather than mouse in-vivo models. For research use only (RUO); not for diagnostic or therapeutic use. CD25 is the 55 kDa alpha chain of the interleukin-2 receptor (IL-2Rα, Tac antigen; UniProt P01589). On its own CD25 binds IL-2 with low affinity; when it assembles with the IL-2Rβ (CD122) and common gamma (CD132) chains it forms the high-affinity heterotrimeric receptor that drives IL-2 signaling through JAK/STAT5, PI3K, and MAPK pathways. CD25 is constitutively high on CD4+FOXP3+ regulatory T cells, where it is a defining marker and supports Treg fitness and immune homeostasis, and it is rapidly upregulated on conventional T and B lymphocytes following activation, making it a classic activation marker. CD25 is also expressed on some leukemias and lymphomas. A soluble form is shed into serum and can serve as an immune-activation biomarker. Because of its central role in T cell tolerance and expansion, CD25 is a well-studied target in autoimmunity, transplantation, and oncology.

IL2RA, Interleukin-2 receptor subunit alpha, TAC, p55

7G7B6

Clone 7G7B6 reacts with human CD25

This monoclonal antibody was purified using Protein A

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and azide free

This antibody is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

ELISA, Flow Cytometry, Immunofluorescence, Immunoprecipitation, Western Blot

Each investigator should determine their own optimal working dilution for specific applications.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

BE0014

Anti-Human CD25/IL2RA (7G7B6) Antibody

Q: Is clone 7G7B6 suitable for in vivo CD25 studies?

A: Yes - 7G7B6 is a low-endotoxin, in vivo-grade antibody suitable for in vivo CD25 studies and in vitro work.

Q: Can I order anti-human CD25 clone 7G7B6 in bulk?

A: Yes, it is manufactured in scalable milligram to gram quantities for bulk and high-throughput experiments.

Q: What does clone 7G7B6 target?

A: It is an anti-human CD25 monoclonal used to study the IL-2 receptor alpha chain on activated T cells and Tregs; for research use only.